- Home
- NXL vs LPCN Comparison
NXL vs LPCN Comparison
Compare NXL & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- LPCN
- Stock Information
- Founded
- NXL 2010
- LPCN 1997
- Country
- NXL United States
- LPCN United States
- Employees
- NXL N/A
- LPCN N/A
- Industry
- NXL Medical Specialities
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NXL Health Care
- LPCN Health Care
- Exchange
- NXL Nasdaq
- LPCN Nasdaq
- Market Cap
- NXL 14.0M
- LPCN 16.1M
- IPO Year
- NXL 2022
- LPCN N/A
- Fundamental
- Price
- NXL $0.85
- LPCN $2.97
- Analyst Decision
- NXL Strong Buy
- LPCN Strong Buy
- Analyst Count
- NXL 1
- LPCN 2
- Target Price
- NXL $5.00
- LPCN $9.00
- AVG Volume (30 Days)
- NXL 2.9M
- LPCN 16.8K
- Earning Date
- NXL 11-07-2025
- LPCN 11-06-2025
- Dividend Yield
- NXL N/A
- LPCN N/A
- EPS Growth
- NXL N/A
- LPCN N/A
- EPS
- NXL N/A
- LPCN N/A
- Revenue
- NXL $174,813.00
- LPCN $4,208,119.00
- Revenue This Year
- NXL $38.28
- LPCN N/A
- Revenue Next Year
- NXL $185.71
- LPCN N/A
- P/E Ratio
- NXL N/A
- LPCN N/A
- Revenue Growth
- NXL 16.42
- LPCN N/A
- 52 Week Low
- NXL $0.59
- LPCN $2.68
- 52 Week High
- NXL $4.49
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- NXL 46.92
- LPCN 48.05
- Support Level
- NXL $0.79
- LPCN $2.87
- Resistance Level
- NXL $0.99
- LPCN $3.00
- Average True Range (ATR)
- NXL 0.08
- LPCN 0.10
- MACD
- NXL 0.01
- LPCN 0.01
- Stochastic Oscillator
- NXL 32.38
- LPCN 41.82
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.